Last reviewed · How we verify
Pneumo23 / Pneumovax
Pneumo23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.
Pneumo23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease (pneumonia, bacteremia, meningitis) in adults and children ≥2 years, Prevention of pneumococcal otitis media and sinusitis.
At a glance
| Generic name | Pneumo23 / Pneumovax |
|---|---|
| Also known as | Antipneumococcal vaccination |
| Sponsor | University Hospital, Montpellier |
| Drug class | Polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified capsular polysaccharides from 23 different pneumococcal serotypes conjugated to a carrier protein or presented as a polyvalent formulation. Upon administration, these antigens trigger B-cell and T-cell responses, leading to the production of opsonizing antibodies that enhance phagocytosis and clearance of pneumococcal bacteria. This provides protection against invasive pneumococcal disease including pneumonia, bacteremia, and meningitis.
Approved indications
- Prevention of invasive pneumococcal disease (pneumonia, bacteremia, meningitis) in adults and children ≥2 years
- Prevention of pneumococcal otitis media and sinusitis
Common side effects
- Injection site erythema or induration
- Injection site pain or soreness
- Fever
- Myalgia or arthralgia
- Headache
Key clinical trials
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (PHASE3)
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (PHASE3)
- Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS (PHASE2, PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumo23 / Pneumovax CI brief — competitive landscape report
- Pneumo23 / Pneumovax updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI